| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M M Byrne, K Gliem, U Wank, R Arnold, M Katschinski, K S Polonsky, B Gök. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes. vol 47. issue 8. 1998-09-09. PMID:9703326. |
the aim of this study was to establish if glucagon-like peptide 1 (glp-1), a natural enteric peptide and potent insulin secretagogue, improves this defect. |
1998-09-09 |
2023-08-12 |
human |
| M M Byrne, K Gliem, U Wank, R Arnold, M Katschinski, K S Polonsky, B Gök. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes. vol 47. issue 8. 1998-09-09. PMID:9703326. |
these results were compatible with enhanced insulin secretion in the presence of glp-1. |
1998-09-09 |
2023-08-12 |
human |
| M M Byrne, K Gliem, U Wank, R Arnold, M Katschinski, K S Polonsky, B Gök. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes. vol 47. issue 8. 1998-09-09. PMID:9703326. |
we concluded that low dosage glp-1 improves the ability of the beta-cell to secrete insulin in both igt and niddm subjects, but that the ability to sense and respond to subtle changes in plasma glucose is improved in igt subjects, with only a variable response in niddm subjects. |
1998-09-09 |
2023-08-12 |
human |
| C Seifarth, J Bergmann, J J Holst, R Ritzel, W Schmiegel, M A Nauc. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association. vol 15. issue 6. 1998-08-27. PMID:9632123. |
plasma levels of glp-1, insulin, c-peptide, glugacon, gip, glucose and h2-exhalation were measured over 6 h. differences in the integrated responses over the observation period were evaluated by repeated measurement analysis of variance with fasting values used as covariates. |
1998-08-27 |
2023-08-12 |
human |
| A Shalev, R Ninnis, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Hormone research. vol 49. issue 5. 1998-08-18. PMID:9568806. |
glucagon-like peptide 1 (glp-1) is known to stimulate insulin secretion and biosynthesis, but has also been shown to decrease insulin requirements in type 1 diabetic subjects suggesting insulin-independent effects. |
1998-08-18 |
2023-08-12 |
human |
| A Shalev, R Ninnis, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Hormone research. vol 49. issue 5. 1998-08-18. PMID:9568806. |
to assess whether glp-1 exerts also direct effects on whole-body glucose metabolism, 6,6-d2-glucose kinetics were measured in 8 healthy volunteers receiving once glp-1, once saline during hyperglycemic glucose clamping, while somatostatin with replacement amounts of insulin, glucagon and growth hormone was infused. |
1998-08-18 |
2023-08-12 |
human |
| A Shalev, R Ninnis, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Hormone research. vol 49. issue 5. 1998-08-18. PMID:9568806. |
even though endogenous insulin secretion could not be blocked completely (increased plasma concentrations of c-peptide and proinsulin), somatostatin infusion resulted in stable insulin and glucagon plasma levels in both protocols (glp-1 vs. placebo: ns). |
1998-08-18 |
2023-08-12 |
human |
| A Shalev, R Ninnis, U Kelle. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Hormone research. vol 49. issue 5. 1998-08-18. PMID:9568806. |
after 3 h of glp-1 infusion, peripheral glucose disappearance significantly increased compared to placebo (p < 0.03) despite of somatostatin-induced suppression of insulin and glucagon secretion. |
1998-08-18 |
2023-08-12 |
human |
| A E Brynes, G S Frost, C M Edwards, M A Ghatei, S R Bloo. Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition (Burbank, Los Angeles County, Calif.). vol 14. issue 5. 1998-08-10. PMID:9614307. |
the gut hormone glucagon-like peptide-1 (7-36) amide (glp-1) is a potent insulin secretagogue. |
1998-08-10 |
2023-08-12 |
human |
| A E Brynes, G S Frost, C M Edwards, M A Ghatei, S R Bloo. Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition (Burbank, Los Angeles County, Calif.). vol 14. issue 5. 1998-08-10. PMID:9614307. |
postprandial plasma glp-1, insulin, and glucose responses were measured in six healthy volunteers in response to a solid test meal and a liquid meal of identical composition. |
1998-08-10 |
2023-08-12 |
human |
| A E Brynes, G S Frost, C M Edwards, M A Ghatei, S R Bloo. Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition (Burbank, Los Angeles County, Calif.). vol 14. issue 5. 1998-08-10. PMID:9614307. |
the type of fat in the soups produced no significant difference in glp-1, insulin, or glucose levels. |
1998-08-10 |
2023-08-12 |
human |
| L Morgan, J Arendt, D Owens, S Folkard, S Hampton, S Deacon, J English, D Ribeiro, K Taylo. Effects of the endogenous clock and sleep time on melatonin, insulin, glucose and lipid metabolism. The Journal of endocrinology. vol 157. issue 3. 1998-08-10. PMID:9691977. |
during each cr salivary melatonin and plasma glucose, triacylglycerol (tag), non-essential fatty acids (nefa), insulin, gastric inhibitory peptide (gip) and glucagon-like peptide-1 (glp-1) were measured hourly. |
1998-08-10 |
2023-08-12 |
human |
| A S Ryan, J M Egan, J F Habener, D Elah. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of clinical endocrinology and metabolism. vol 83. issue 7. 1998-07-29. PMID:9661618. |
glucagon-like peptide-1 (glp-1) is an intestinal insulinotropic hormone that augments insulin secretion in response to meals and lowers blood glucose levels in both type 1 and type 2 diabetic subjects. |
1998-07-29 |
2023-08-12 |
human |
| A S Ryan, J M Egan, J F Habener, D Elah. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of clinical endocrinology and metabolism. vol 83. issue 7. 1998-07-29. PMID:9661618. |
after the glp-1 study, each individual's plasma insulin level was measured. |
1998-07-29 |
2023-08-12 |
human |
| A S Ryan, J M Egan, J F Habener, D Elah. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of clinical endocrinology and metabolism. vol 83. issue 7. 1998-07-29. PMID:9661618. |
a second study was performed that was identical to the first, with the infusion of regular insulin in place of glp-1. |
1998-07-29 |
2023-08-12 |
human |
| A S Ryan, J M Egan, J F Habener, D Elah. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of clinical endocrinology and metabolism. vol 83. issue 7. 1998-07-29. PMID:9661618. |
insulin infusion rates were designed in each individual to simulate plasma insulin levels produced during the glp-1 infusion. |
1998-07-29 |
2023-08-12 |
human |
| A S Ryan, J M Egan, J F Habener, D Elah. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of clinical endocrinology and metabolism. vol 83. issue 7. 1998-07-29. PMID:9661618. |
in response to the glp-1 infusion, although basal plasma glucose levels were clamped, significant increases in insulin occurred in all subjects (p < 0.001). |
1998-07-29 |
2023-08-12 |
human |
| A S Ryan, J M Egan, J F Habener, D Elah. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of clinical endocrinology and metabolism. vol 83. issue 7. 1998-07-29. PMID:9661618. |
with the nearly identical plasma insulin levels during the two studies (30-60 min levels: glp-1 study, 151 +/- 48; insulin study, 146 +/- 31 pmol/l), the rate of disappearance of glucose progressively increased in response to both glp-1 and insulin infusions, but was not significantly different between the studies. |
1998-07-29 |
2023-08-12 |
human |
| N N Kok, L M Morgan, C M Williams, M B Roberfroid, J P Thissen, N M Delzenn. Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats. The Journal of nutrition. vol 128. issue 7. 1998-07-23. PMID:9649591. |
because glucose, insulin, insulin-like growth factor i (igf-i) and gut peptides [i.e., glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1)]) are factors involved in the metabolic response to nutrients, this paper analyzes their putative role in the hypolipidemic effect of oligofructose. |
1998-07-23 |
2023-08-12 |
rat |
| M I López-Delgado, M Morales, M L Villanueva-Peñacarrillo, W J Malaisse, I Valverd. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology. vol 139. issue 6. 1998-06-24. PMID:9607788. |
the basal activity of glycogen synthase a and the relative extent of its inhibition by glucagon or activation by insulin and glp-1 were modulated by the extracellular concentration of d-glucose. |
1998-06-24 |
2023-08-12 |
rat |